

Product Data Sheet

ET receptor antagonist 1

Cat. No.: HY-155737 Molecular Formula: ${\sf C_{21}H_{25}N_5O_5S}$ Molecular Weight: 459.52

Target: Estrogen Receptor/ERR

Pathway: Vitamin D Related/Nuclear Receptor

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

BIOLOGICAL ACTIVITY

Description	ET receptor antagonist 1 (compound 16h) is an orally active ET receptor antagonist (IC ₅₀ =0.18 nM), which can be used for research in pulmonary arterial hypertension (PAH). ET receptor antagonist 1 attenuates monocrotaline (HY-N0750) induced PAH in rat model ^[1] .
IC ₅₀ & Target	IC50: 0.18 nM (ET receptor) ^[1]
In Vivo	ET receptor antagonist 1 (compound 16h) (150 mg/kg/d, 300 mg/kg/d; po; 48 h following MCT administration, for 21-26 d) results significant reduction in mPAP, and decreases the levels of HIF1 α , ANP, and TNNI3 in MCT-exposed rats. And shows antioxidant profile and inhibits lipid peroxidation ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Panchal J, et al. Development of novel bosentan analogues as endothelin receptor antagonists for pulmonary arterial hypertension. Eur J Med Chem. 2023 Nov 5;259:115681.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA